article thumbnail

Leading innovators in zinc-finger nucleases for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Genetics 130
article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

Predictable milestones and future perspectives Transposons (genetic elements) have been used to deliver a gene of interest into transcriptionally active sites of the cell line genome leading to rapid cell line development eventually resulting in high titers of the recombinant protein drug.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New nasal spray treats Delta variant infection in mice, indicating broad spectrum results

The Pharma Data

In a preprint, the researchers at Cornell University led by Associate Professor Hector Aguilar-Carreno showed that genetically engineered mice infected with the virus causing COVID-19 and given a daily dose of the compound in a nasal spray for four days. 2 around the world.” Shapira, T., Monreal, I.A.,

article thumbnail

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

Roots Analysis

The IVT mRNAs are structurally similar to natural mRNAs, these synthetic mRNAs can be used to express proteins through genetic engineering. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

article thumbnail

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.

Gene 262
article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

The presentations include: Mark Cragg, PhD, Professor of Experimental Cancer Biology, Antibody and Vaccine Group, School of Cancer Sciences, University of Southampton, on: ‘Modulating antibody effector functions in the tumour microenvironment’.